The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis
Objectives: The aim of this study was to examine the effectof smoking on the efficacy of raloxifene treatment inpostmenopausal osteoporosis.Materials and methods: In this cross-sectional study,raloxifene HCl (60 mg/day) and 600 mg ionized calcium+ 400 IU vitamin D/day treatment were given to 63 case...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Modestum Publishing LTD
2012-12-01
|
Series: | Journal of Clinical and Experimental Investigations |
Subjects: | |
Online Access: | http://www.jceionline.org/upload/sayi/11/JCEI-00507.pdf |
id |
doaj-795fff22a1d94b89a2294b441bfac014 |
---|---|
record_format |
Article |
spelling |
doaj-795fff22a1d94b89a2294b441bfac0142021-09-02T16:04:15ZengModestum Publishing LTDJournal of Clinical and Experimental Investigations1309-85781309-66212012-12-0134457462The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosisSavaş ErdemAyşe Filiz Yavuz AvşarHüseyin Levent KeskinGülin Feykan Yeğin AkçayElçin İşlek SeçenObjectives: The aim of this study was to examine the effectof smoking on the efficacy of raloxifene treatment inpostmenopausal osteoporosis.Materials and methods: In this cross-sectional study,raloxifene HCl (60 mg/day) and 600 mg ionized calcium+ 400 IU vitamin D/day treatment were given to 63 cases(nonsmoker group n= 39, smoker group n= 24), who werein the postmenopausal period and detected as having osteoporosis.At the end of the first year of the treatment, thebone mineral densities (BMDs; g/cm2) were measured atfour regions, namely the femur neck, femur trochanter, totalhip, and lumbar vertebrae between L1-4, and T-scoreswere determined. The changes in BMDs were comparedbetween the two groups.Results: Before starting the treatment, the mean ages(55.8 ± 3.3 vs. 53.0 ± 1.3 years), menopausal ages (49.3± 2.9 vs. 48.1 ± 2.1 years), postmenopausal periods (5.0± 1.3 vs. 7.0 ± 1.4 years), body mass indexes, and estradiollevels were found to be significantly not differentbetween the two groups (p > 0.05). At the beginning oftreatment, the BMD values were not different for all measuredregions in both groups (p > 0.05). At the end of thefirst year of the treatment, statistically significant improvementsin BMD values and T-scores were detected for allmeasured regions in the nonsmoker group (p < 0.05).However, there were no significant differences in theBMD values from the initial values in the smoker groupafter treatment (p > 0.05).Conclusions: The treatment efficacy of raloxifene in improvingBMD values in postmenopausal osteoporosis isnegatively influenced by smoking. J Clin Exp Invest 2012;3(4): 457-462Key words: Raloxifene, postmenopausal osteoporosis,smokinghttp://www.jceionline.org/upload/sayi/11/JCEI-00507.pdfRaloxifenepostmenopausal osteoporosissmoking |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Savaş Erdem Ayşe Filiz Yavuz Avşar Hüseyin Levent Keskin Gülin Feykan Yeğin Akçay Elçin İşlek Seçen |
spellingShingle |
Savaş Erdem Ayşe Filiz Yavuz Avşar Hüseyin Levent Keskin Gülin Feykan Yeğin Akçay Elçin İşlek Seçen The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis Journal of Clinical and Experimental Investigations Raloxifene postmenopausal osteoporosis smoking |
author_facet |
Savaş Erdem Ayşe Filiz Yavuz Avşar Hüseyin Levent Keskin Gülin Feykan Yeğin Akçay Elçin İşlek Seçen |
author_sort |
Savaş Erdem |
title |
The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis |
title_short |
The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis |
title_full |
The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis |
title_fullStr |
The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis |
title_full_unstemmed |
The effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis |
title_sort |
effect of smoking on the response to raloxifene treatment in postmenopausal osteoporosis |
publisher |
Modestum Publishing LTD |
series |
Journal of Clinical and Experimental Investigations |
issn |
1309-8578 1309-6621 |
publishDate |
2012-12-01 |
description |
Objectives: The aim of this study was to examine the effectof smoking on the efficacy of raloxifene treatment inpostmenopausal osteoporosis.Materials and methods: In this cross-sectional study,raloxifene HCl (60 mg/day) and 600 mg ionized calcium+ 400 IU vitamin D/day treatment were given to 63 cases(nonsmoker group n= 39, smoker group n= 24), who werein the postmenopausal period and detected as having osteoporosis.At the end of the first year of the treatment, thebone mineral densities (BMDs; g/cm2) were measured atfour regions, namely the femur neck, femur trochanter, totalhip, and lumbar vertebrae between L1-4, and T-scoreswere determined. The changes in BMDs were comparedbetween the two groups.Results: Before starting the treatment, the mean ages(55.8 ± 3.3 vs. 53.0 ± 1.3 years), menopausal ages (49.3± 2.9 vs. 48.1 ± 2.1 years), postmenopausal periods (5.0± 1.3 vs. 7.0 ± 1.4 years), body mass indexes, and estradiollevels were found to be significantly not differentbetween the two groups (p > 0.05). At the beginning oftreatment, the BMD values were not different for all measuredregions in both groups (p > 0.05). At the end of thefirst year of the treatment, statistically significant improvementsin BMD values and T-scores were detected for allmeasured regions in the nonsmoker group (p < 0.05).However, there were no significant differences in theBMD values from the initial values in the smoker groupafter treatment (p > 0.05).Conclusions: The treatment efficacy of raloxifene in improvingBMD values in postmenopausal osteoporosis isnegatively influenced by smoking. J Clin Exp Invest 2012;3(4): 457-462Key words: Raloxifene, postmenopausal osteoporosis,smoking |
topic |
Raloxifene postmenopausal osteoporosis smoking |
url |
http://www.jceionline.org/upload/sayi/11/JCEI-00507.pdf |
work_keys_str_mv |
AT savaserdem theeffectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT aysefilizyavuzavsar theeffectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT huseyinleventkeskin theeffectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT gulinfeykanyeginakcay theeffectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT elcinisleksecen theeffectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT savaserdem effectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT aysefilizyavuzavsar effectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT huseyinleventkeskin effectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT gulinfeykanyeginakcay effectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis AT elcinisleksecen effectofsmokingontheresponsetoraloxifenetreatmentinpostmenopausalosteoporosis |
_version_ |
1721172993183318016 |